glp-1 overdose receptor agonists show promise in treating substance use disorders How a GLP-1 overdose sent
Description
Two leading glucagon-like peptide-1 (GLP-1) receptor agonists for obesity and type 2 diabetes Novo Nordisk A/Ss semaglutide (Wegovy/Ozempic) and Eli Lilly and Co.s tirzepatide (Mounjaro/Zepbound) are advancing in China after taking the U.S
Patients taking Ozempic and Wegovy say their hair is starting to fall out
Welcome to Hospitalogy, a newsletter breaking down healthcare finance, M&A, and strategy twice weekly
Stool softeners don't address the root cause
If a product has not been FDA-approved for a specific condition, it cannot be promoted as safe or effective for that condition
